Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 24, 835-840, June 1, 1964]
© 1964 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LePage, G. A.
Right arrow Articles by Bowman, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LePage, G. A.
Right arrow Articles by Bowman, B.

Biochemical and Carcinostatic Effects of 2'-Deoxythioguanosine*

G. A. LePage, Irene G. Junga and Bettie Bowman

( Life Sciences Research, Stanford Research Institute, Menlo Park, California)

The {alpha}- and ß-anomers of 2'-deoxythioguanosine were studied in mice, in comparison with thioguanine riboside and thioguanine, as to host toxicity, capacity to become incorporated into nucleic acid nucleotides, and therapeutic effects on mammary tumors of C3H mice. They were also tested on several thioguanine-resistant ascites cell tumors of mice. The ß-anomer, thioguanine riboside, and thioguanine appear to be of approximately equal toxicity on a molar basis. The {alpha}-anomer was found to be much less toxic. The ß-anomer was superior to thioguanine or the other nucleosides in the treatment of C3H mammary tumors.

In two types of resistance to thioguanine, that resulting from lack of the phosphoribosylpyrophosphorylase for the formation of nucleotide from thioguanine and that resulting from poor capacity for conversion of ribotides to deoxyribotides, the deoxyribonucleosides of thioguanine appear to have utility.

* This work was supported in part by Contract No. SA-43-ph-3068 with the Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health; and in part by United States Public Health Service Grant No. CY-4551.

Received 12/16/63.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1964 by the American Association for Cancer Research.